Skip to main content

Drug Interactions between marstacimab and prothrombin complex

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

prothrombin complex marstacimab

Applies to: prothrombin complex and marstacimab

Consumer information for this interaction is not currently available.

MONITOR: Although factor VIII (fVIII) and factor IX (fIX) products are used in clinical practice to treat breakthrough bleeding in patients receiving marstacimab prophylaxis, coadministration with clotting factors may have synergistic effects on thrombin generation and increase the risk of thrombosis. An interaction study in mice demonstrated slightly increased peak thrombin levels when marstacimab was coadministered with recombinant factor VIIa or activated prothrombin, compared to either agent alone. The observed increase was within the reported range for nonhemophilic plasma and did not generate excessive thrombin. Clinical data are not available and the extent to which other coagulation factors may interact with marstacimab is unknown.

MANAGEMENT: Caution and monitoring are recommended with if treatment for breakthrough bleeding is necessary during marstacimab prophylaxis. The manufacturer recommends that if treatment with factor VIII or factor IX is indicated, the minimum effective dose should be considered. Patients should be advised to seek immediate medical attention if they experience signs or symptoms of thromboembolism. In addition, a cautious approach is advised in patients with previous histories of thromboembolic events, as marstacimab has not been studied in these patients.

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.